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 EDITORIAL EDITORIAL
On November 18, 2010, the European 
Medicine Agency (EMA) released a draft 
guideline on similar medicinal prod-
ucts containing monoclonal antibodies 
(mAbs), following a workshop organized 
by the agency in London on July 2, 2009.1 
The guideline discusses relevant animal 
model, non-clinical and clinical stud-
ies that are recommended to establish 
the similarity and the safety of a bio-
similar compared to an originator mAb 
approved in the European Union (EU). 
The end of consultation and the deadline 
for comments is May 2011. Legislation 
establishing an abbreviated approval path-
way for biosimilars was signed into law 
in March 2010 in the US and the Food 
and Drug Administration (FDA) is cur-
rently working to define the rules for its 
implementation.2
To contribute to the debate, the Editor-
in-Chief and the Associate Editor of mAbs 
encourage the submission of manuscripts 
on biosimilar mAbs including views, 
commentary and research reports from 
regulatory authorities, originator, generic 
laboratories, academic scientists and pat-
ent attorneys of different regions. These 
should explain various situations and 
standpoints as recently discussed during 
the 6th European Antibody Congress3 
and encourage additional dialog. To start 
the process, in this issue of mAbs, Mark 
McCarmish (Sandoz) details the advan-
tages of strategies aiming to produce 
highly similar antibodies. Future issues 
will contain position papers from a US 
originator company, an Asia biosimilar 
company and others.
Biosimilars, follow-on biologics, bioge-
nerics, biobetters, biosuperiors, second and 
third generation antibodies are terms used 
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in a sometimes confusing way.4 To con-
tribute to the clarification of the debate, 
the aim of this editorial is to propose defi-
nitions and provide examples for these dif-
ferent categories of mAbs (Table 1).
Biosimilar antibodies are “generic” 
versions of “innovator” (or “origina-
tor”) antibodies with the same amino 
acid sequence, but produced from differ-
ent clones and manufacturing processes. 
As a consequence, biosimilar mAbs may 
include possible differences in glycosyl-
ation and other microvariations such 
as charge variants that may affect qual-
ity, safety and potency.5,6 Biosimilars are 
known as follow-on biologics in the US 
but this term is misleading because it 
could also refer to second and third gener-
ation antibodies (that will be defined and 
illustrated below) and should be avoided. 
In contrast to the low-cost generic versions 
of small molecules that are off patent, it 
is currently not possible to produce exact 
copies of large proteins and glycoproteins, 
such as antibodies, owing to their struc-
tural complexity, and so the term biogene-
ric should also be avoided. Nevertheless, 
tremendous progress has been made in 
bioproduction and analytical sciences, 
and it is now possible to produce proteins 
and glycoproteins that are similar to ref-
erence products. The EMA has pioneered 
the regulatory framework for approval of 
these products. Since 2005, EMA has ini-
tiated regulatory pathways for biosimilar 
products, resulting to date in marketing 
authorization in Europe for 13 recombi-
nant drugs encompassing three product 
classes (human growth hormone, granulo-
cyte colony-stimulating factor and eryth-
ropoietins). Specific guidelines are also 
available in Europe for biosimilar insulin, 
interferon and low molecular weight hepa-
rins (LMWH).
Outside Europe, the first wave of bio-
similar antibodies were copies of current 
important therapeutic antibodies such as a 
biosimilar rituximab, which is approved in 
India (Reditux; Dr. Reddy’s Laboratories) 
and a biosimilar abciximab, which is 
approved in South Korea (Clotinab; Abu 
Abxis). Rituximab and abciximab were 
originally discovered and developed by 
Genentech/Roche/BiogenIdec (Rituxan/
Mabthera) and Centocor (Reopro), respec-
tively.7 Further biosimilar candidates cur-
rently in development include copies of 
infliximab (Remicade; Centocor/Merck), 
trastuzumab (Herceptin; Genentech/
Roche), cetuximab (Erbitux; ImClone/
Lilly & Merck-Serono), bevacizumab 
(Avastin; Genentech/Roche) and etan-
ercept, an Fc-fusion protein (Enbrel; 
Amgen/Wyeth).
Bio-better antibodies are antibodies   
that target the same validated epitope 
as a marketed antibody, but have been 
engineered to have improved properties, 
e.g., optimized glycosylation profiles to 
enhance effector functions or an engi-
neered Fc domain to increase the serum 
half-life.8 Such “Me better” antibodies with 
controlled and optimized glycosylation 
have been obtained in glyco-engineered 
CHO cells or yeast strains, e.g., copies of 
rituximab and trastuzumab amino acid 
sequences with afucosylated glycoforms 
that result in a 40- to 100-fold increase 
in ADCC,9,10 or with increased plasmatic 
half-life, e.g., copies of rituximab, trastu-
zumab, bevacizumab that have a muta-
tion of two or three amino acids in the 
Fc domain resulting in extended phar-
macokinetics.11 In these cases, the cost of 108  mAbs  Volume 3 Issue 2
Table 1. Selected examples of first generation, Biosimilars, Biobetter, second and third generation monoclonal antibodies and alternatives formats
1st generation mAbs Biosimilars Biobetters 2nd generation 3nd generation Alternative formats
CD20
Rituximab (1997) 
chIgG1 (CHO) 
(Rituxan/Mabthera)
Reditux  
(2007, Dr. Reddy) 
chIgG1 (CHO)
“Rituximab” GS4:0 
aFuc hzIgG1  
(Pichia pastoris) 
Same epitope
Ofatumumab (2009) 
hIgG1 (CHO) 
Different epitope and 
mechanism of action 
(MOA) 
(Arzerra)
Obinutuzumab (PhIII) 
aFuc hIgG1 (CHO) 
Different epitope 
and MOA
TRU-015 (PhIIb) 
SMIP
TL011  
(PhI, Teva/Lonza) 
chIgG1 (CHO)
Ocrelizumab (PhIII) 
hzIgG1 (CHO) 
Same epitope
TNFa
Infliximab (1998) 
chIgG1 (SP2/0) 
(Remicade)
TNFmab (Pre-clin, 
LGLS)
Adalimumab (2002) 
huIgG1 (CHO) 
(Humira)
Certolizumab (2008) 
Fab-PEG (E. coli) 
(Cimzia)
CT-P13 « infliximab » 
(PhIII, Celltrion)
Golimumab (2009) 
huIgG1 (CHO) 
s.c. every 4 wk 
(Simponi)
Etanercept (1998) 
TNFR-Fc (CHO) 
(Enbrel)
TNFcept (PhI, LGLS)
HER2
Trastuzumab (1998) 
chIgG1 (CHO) 
(Herceptin)
CT-P6 « trastuzumab » 
(PhIII, Celltrion)
Trastuzumab s.c. for-
mulation every 4 wk 
(PhIII)
Pertuzumab (PhIII) 
huIgG1 (CHO) 
Different epitope  
(targets HER2  
and HER3)
Trastuzumab  
emtansine (PhIII) 
Antibody Drug 
Conjugate 
(targets HER2  
and tubulin)
“Trastuzumab” GFI5:0 
aFuc hzIgG1  
(Pichia pastoris) 
Same epitope
2 in 1, bispecific 
(targets HER2  
and VEGFA)
EGFR
Cetuximab (2004) 
chIgG1 (SP2/0) 
(Erbitux)
CMAB009 (PhI) 
chIgG1 (CHO)
Necitumumab (PhIII) 
huIgG1 (CHO) 
Same epitope
Xtend EGFR, M428L/
N434S 
hzIgG1 (CHO) 
Fc-engineered  
(longer half life) 
Same epitope
VEGF-A
Bevacizumab (2004) 
hzIgG1 (CHO) 
(Avastin)
Xtend VEGF, M428L/
N434S 
hzlgG1 (CHO) 
Fc-engineered  
(longer half life) 
Same epitope
Ranibizumab 
Fab, affinity matu-
rated (E. coli) 
(Lucentis)
2 in 1, bispecific 
(targets HER2  
and VEGFA)
RSV—Prot F
Palivizumab (1998) 
hzIgG1 (NS0) 
(Synagis)
Motavizumab (PhIII, 
stopped) 
hzIgG1 affinity matu-
rated (NS0) 
(Numax)
Motavizumab-
YTE, long-lasting 
Fc-engineered  
version (PhI)
Note: Adapted from reference 4 and updated from reference 22 (6th European Antibody Congress 2010).www.landesbioscience.com mAbs  109
antibody motavizumab (MEDI-524; 
MedImmune), which has affinity matured 
complementarity determining regions 
(CDRs), and then by the third generation 
antibody MEDI-557 (MedImmune), a 
version of motavizumab with engineered 
Fc domains for a longer serum half-life, 
that is in a Phase 1 study.
The development of legal and regula-
tory pathways for biosimilars mAbs will 
continue to raise much debate among law-
makers, regulators, originator and generic 
industry, patent attorneys, academia and 
health care professionals, and mAbs looks 
forward to contributing to the discussions.
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a CHO-produced version of cetuximab 
(CHO-C225). A bio-better version of 
cetuximab produced in CHO cells is cur-
rently in development in China.15
Second-generation antibodies are fol-
low-up antibodies with improved variable 
domains (such as humanized or human 
variable domains or affinity matured 
CDRs).4 Blockbuster antibodies, such 
as rituximab, infliximab, trastuzumab 
and cetuximab, are directed against the 
now highly clinically validated targets 
CD20, tumor necrosis factor (TNF), 
human epidermal growth factor recep-
tor 2 (HER2)16 and EGFR, respectively. 
Second-generation antibodies directed 
against these same antigens have altera-
tions, such as improved variable domains 
to decrease immunogenicity, target dis-
tinct epitopes with higher or lower affin-
ity for their antigens, or have different 
antibody formats, e.g., conjugation of 
the Fab domain to polyethylene glycol 
(PEGylation) and Fc-fusion proteins. 
These antibodies have been investigated 
in the clinic and recently approved for use 
in several diseases. Examples include pani-
tumumab (Vectibix; Amgen), which fol-
lowed cetuximab; ofatumumab (Arzerra; 
Genmab/GlaxoSmithKline), which 
followed rituximab and adalimumab 
(Humira/Trudexa; Abbott), certolizumab 
pegol (Cimzia, UCB) and golimumab 
(Simponi; Centocor), all of which fol-
lowed infliximab. These successful first 
generation antibodies are also being fol-
lowed by antibody-drug conjugates deriv-
atives, e.g., trastuzumab emtansine17 and 
bispecific versions, e.g., antibody targeting 
both HER2 and VEGF.18
In addition, third-generation anti-
bodies, targeting different epitopes, trig-
gering other mechanisms of action and 
that are often engineered for improved 
Fc-associated immune functions or half-
life, have also reached Phase 1 to 3 clinical 
trials.19 For example, the third-generation 
CD20-specific antibody obinutuzumab 
(GA101; Glycart/Roche/BiogenIdec) is 
less immunogenic than rituximab, has 
a different mechanism of action and is 
glycoengineered to trigger increased cyto-
toxicity.20,21 Another example is the respi-
ratory syncytial virus-specific palivizumab 
(Synagis; MedImmune/Abbott), which 
was followed by the second-generation 
treatment is expected to decrease because 
of lower cost of the products, less frequent 
administration regimens or lower dosages.
Cetuximab, a chimeric mouse-human 
IgG1 targeting epidermal growth fac-
tor receptor (EGFR), is approved for 
use in the EU and US as a treatment for 
colorectal cancer and squamous cell car-
cinoma of the head and neck.12 A high 
prevalence of hypersensitivity reactions 
to cetuximab has been reported in some 
areas of the US. Among 76 cetuximab-
treated subjects, 25 had a hypersensitivity 
reaction to the drug.13 The IgE antibodies 
thought to be responsible for the reaction 
were shown to be specific for an oligosac-
charide, galactose-α-1,3-galactose, that is 
present on the Fab portion of the cetux-
imab heavy chain when the molecule is 
produced in the murine SP2/0 cell line 
used for commercial manufacturing, but 
not in the CHO cells used as control. 
The mechanism underlying a hypersen-
sitivity reaction to cetuximab involves 
pre-existing IgE antibodies that target an 
oligosaccharide present on the recombi-
nant molecule produced in the SP2/0 cell 
line. These results have implications for 
evaluating risks associated with antibody-
based therapeutics and for understanding 
the relevance of IgE antibodies specific 
for post-translational modifications of 
natural and recombinant molecules. The 
second N-glycosylation site in the Fab 
portion on heavy chain Asn88 of cetux-
imab is of prime importance. For the mar-
keted version of cetuximab produced in 
SP2/0 cells, 21 different glycoforms were 
identified with around 30% capped by 
at least one a-1,3-galactose residue, 12% 
capped by a N-glycolylneuraminic acid 
(NGNA) residue and traces of oligoman-
nose.14 Importantly, both a-1,3-galactose 
and NGNA were found only in the Fab 
moieties, rather than the Fc fragment 
for which only typical IgGs G0F, G1F 
and G2F glycoforms were identified. In 
cases of cetuximab-induced anaphylaxis, 
pre-existing IgEs specific for this alpha-
1,3-galactose epitope were detected in 
patients treated with cetuximab. Using 
a solid phase immunoassay, these IgEs 
were found to bind to SP2/0 produced 
cetuximab and F(ab’)2 fragment, but 
not to the Fc fragment. Interestingly, no 
IgE immunoreactivity was found against 110  mAbs  Volume 3 Issue 2
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